Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.22 Million CAD | 67.44% |
| 2022 | -3.76 Million CAD | -54.44% |
| 2021 | -2.43 Million CAD | 94.55% |
| 2020 | -44.71 Million CAD | -2921.22% |
| 2019 | -1.48 Million CAD | 58.58% |
| 2018 | -3.57 Million CAD | -91.49% |
| 2017 | -1.86 Million CAD | 10.09% |
| 2016 | -2.07 Million CAD | -201.13% |
| 2015 | -689.15 Thousand CAD | 66.56% |
| 2014 | -2.06 Million CAD | -682.75% |
| 2013 | -263.29 Thousand CAD | 96.01% |
| 2012 | -6.59 Million CAD | -99.14% |
| 2011 | -3.31 Million CAD | -30.59% |
| 2010 | -2.53 Million CAD | -42.34% |
| 2009 | -1.78 Million CAD | -252.45% |
| 2008 | -505.68 Thousand CAD | 2.03% |
| 2007 | -516.15 Thousand CAD | -490.57% |
| 2006 | -87.4 Thousand CAD | -39.7% |
| 2005 | -62.56 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -90.57 Thousand CAD | 37.26% |
| 2024 Q1 | -144.37 Thousand CAD | 31.1% |
| 2023 Q2 | -302.79 Thousand CAD | 42.65% |
| 2023 Q1 | -528 Thousand CAD | 78.68% |
| 2023 Q4 | -209.56 Thousand CAD | -13.85% |
| 2023 Q3 | -184.06 Thousand CAD | 39.21% |
| 2023 FY | -1.22 Million CAD | 67.44% |
| 2022 Q4 | -2.47 Million CAD | -726.44% |
| 2022 FY | -3.76 Million CAD | -54.44% |
| 2022 Q1 | -662.11 Thousand CAD | -171.8% |
| 2022 Q2 | -302.29 Thousand CAD | 54.34% |
| 2022 Q3 | -299.65 Thousand CAD | 0.88% |
| 2021 Q4 | -243.6 Thousand CAD | 82.64% |
| 2021 FY | -2.43 Million CAD | 94.55% |
| 2021 Q3 | -1.4 Million CAD | -233.32% |
| 2021 Q2 | -420.96 Thousand CAD | 31.76% |
| 2021 Q1 | -616.89 Thousand CAD | 96.16% |
| 2020 Q4 | -16.08 Million CAD | -2800.87% |
| 2020 Q1 | -183.78 Thousand CAD | 26.65% |
| 2020 FY | -44.71 Million CAD | -2921.22% |
| 2020 Q2 | -6.42 Million CAD | -3396.18% |
| 2020 Q3 | -554.49 Thousand CAD | 91.37% |
| 2019 Q3 | -343.87 Thousand CAD | 26.92% |
| 2019 Q2 | -470.52 Thousand CAD | -41.24% |
| 2019 Q1 | -333.13 Thousand CAD | 39.4% |
| 2019 Q4 | -250.54 Thousand CAD | 27.14% |
| 2019 FY | -1.48 Million CAD | 58.58% |
| 2018 Q2 | -194.67 Thousand CAD | 90.61% |
| 2018 Q3 | -755.38 Thousand CAD | -288.02% |
| 2018 FY | -3.57 Million CAD | -91.49% |
| 2018 Q1 | -2.07 Million CAD | -160.26% |
| 2018 Q4 | -549.69 Thousand CAD | 27.23% |
| 2017 Q3 | -468.18 Thousand CAD | -39.85% |
| 2017 FY | -1.86 Million CAD | 10.09% |
| 2017 Q2 | -334.78 Thousand CAD | -25.77% |
| 2017 Q1 | -266.18 Thousand CAD | 83.34% |
| 2017 Q4 | -796.62 Thousand CAD | -70.15% |
| 2016 Q3 | -194.05 Thousand CAD | 2.08% |
| 2016 Q1 | -85.19 Thousand CAD | 64.39% |
| 2016 FY | -2.07 Million CAD | -201.13% |
| 2016 Q2 | -198.17 Thousand CAD | -132.62% |
| 2016 Q4 | -1.59 Million CAD | -723.42% |
| 2015 FY | -689.15 Thousand CAD | 66.56% |
| 2015 Q1 | -167.71 Thousand CAD | 90.34% |
| 2015 Q2 | -111.28 Thousand CAD | 33.65% |
| 2015 Q3 | -170.89 Thousand CAD | -53.57% |
| 2015 Q4 | -239.25 Thousand CAD | -40.0% |
| 2014 Q1 | -72.51 Thousand CAD | 20.6% |
| 2014 Q4 | -1.73 Million CAD | -1358.89% |
| 2014 FY | -2.06 Million CAD | -682.75% |
| 2014 Q3 | -119.01 Thousand CAD | 10.55% |
| 2014 Q2 | -133.05 Thousand CAD | -83.49% |
| 2013 Q1 | -57.06 Thousand CAD | 99.06% |
| 2013 FY | -263.29 Thousand CAD | 96.01% |
| 2013 Q2 | -24.46 Thousand CAD | 57.13% |
| 2013 Q4 | -91.32 Thousand CAD | -0.98% |
| 2013 Q3 | -90.43 Thousand CAD | -269.65% |
| 2012 Q1 | -171.36 Thousand CAD | 92.93% |
| 2012 FY | -6.59 Million CAD | -99.14% |
| 2012 Q3 | -210.18 Thousand CAD | -77.75% |
| 2012 Q4 | -6.09 Million CAD | -2801.3% |
| 2012 Q2 | -118.24 Thousand CAD | 31.0% |
| 2011 Q2 | -451.35 Thousand CAD | -102.25% |
| 2011 Q1 | -223.16 Thousand CAD | 69.31% |
| 2011 Q3 | -214.78 Thousand CAD | 52.41% |
| 2011 FY | -3.31 Million CAD | -30.59% |
| 2011 Q4 | -2.42 Million CAD | -1028.51% |
| 2010 Q3 | -314.64 Thousand CAD | -89.7% |
| 2010 Q1 | -1.32 Million CAD | -295.89% |
| 2010 Q4 | -727.18 Thousand CAD | -131.11% |
| 2010 Q2 | -165.86 Thousand CAD | 87.52% |
| 2010 FY | -2.53 Million CAD | -42.34% |
| 2009 Q4 | -335.76 Thousand CAD | 27.32% |
| 2009 FY | -1.78 Million CAD | -252.45% |
| 2009 Q3 | -462 Thousand CAD | -22.45% |
| 2009 Q2 | -377.28 Thousand CAD | 37.87% |
| 2009 Q1 | -607.23 Thousand CAD | -1281.36% |
| 2008 Q2 | -187.77 Thousand CAD | -270.14% |
| 2008 Q3 | -318.57 Thousand CAD | -69.66% |
| 2008 FY | -505.68 Thousand CAD | 2.03% |
| 2008 Q1 | -50.73 Thousand CAD | 77.47% |
| 2008 Q4 | 51.4 Thousand CAD | 116.13% |
| 2007 Q4 | -225.17 Thousand CAD | -126.38% |
| 2007 Q1 | -96.67 Thousand CAD | -140.64% |
| 2007 Q3 | -99.46 Thousand CAD | -4.89% |
| 2007 Q2 | -94.83 Thousand CAD | 1.91% |
| 2007 FY | -516.15 Thousand CAD | -490.57% |
| 2006 Q3 | -16.91 Thousand CAD | -11.59% |
| 2006 FY | -87.4 Thousand CAD | -39.7% |
| 2006 Q1 | -15.15 Thousand CAD | 0.0% |
| 2006 Q4 | -40.17 Thousand CAD | -137.54% |
| 2006 Q2 | -15.15 Thousand CAD | 0.0% |
| 2005 FY | -62.56 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 81.944% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 85.118% |
| BetterLife Pharma Inc. | -2.88 Million CAD | 57.618% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 84.072% |
| ChitogenX Inc. | -1.55 Million CAD | 21.208% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | 71.568% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 90.719% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -308.139% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 76.529% |
| Glow Lifetech Corp. | -1.64 Million CAD | 25.595% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -41.109% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -57.015% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -260.285% |
| MYND Life Sciences Inc. | -1.51 Million CAD | 19.332% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | 60.697% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | 3.927% |
| Telescope Innovations Corp. | -5.72 Million CAD | 78.621% |